It was announced today that big pharma giant Bayer will acquire Monsanto and their poisonous goodies for an estimated $66 billion dollars.
The German pharmaceutical company agreed to buy the American GMO company for $128 a share. The acquisition values Monsanto’s equity at approximately $56 billion, but including debt, the deal is worth nearly $66 billion.
The latest bid offered by Bayer is 22 percent above Monsanto’s closing price on the New York Stock Exchange on Tuesday.
The acquisition of the leading GMO maker will make Bayer the world’s biggest seed and pesticide producer. The takeover is expected to be closely scrutinized by antitrust regulators.
The deal will potentially leave just a few large global players in the crop and seed industry. American conglomerate DuPont reportedly plans to merge with the Dow Chemical Company and China National Chemical Corporation is set to acquire Swiss agribusiness Syngenta.
Last week, Bayer raised its offer aiming to complete the deal that had been negotiated for more than four months.
Monsanto is as one of the world’s leading manufacturers of genetically modified seeds. The company has long been criticized in Europe, with many consumers skeptical of GMO-derived produce.
Bayer has signed a deal that includes a fee of $2 billion should the transaction fail to get regulatory clearance as planned, a source told Reuters. It should be closed by the end of 2017.
Founded over 150 years ago, Bayer made its name by introducing heroin as a cough remedy in 1896 and then aspirin in 1899. The German company has become one the global leaders in the pharmaceutical and chemical industries.
Latest posts by Carol Adl (see all)
- If Elected Prime Minister Corbyn Would Suspend UK Airstrikes In Syria - April 24, 2017
- Russia Is Ready To Deploy Ground Troops To Syria - April 24, 2017
- Former Defense Minister Admits Israel’s Tacit Alliance With ISIS In Syria - April 24, 2017